Jiangsu Recbio Begins Phase III Trial for New Shingles Vaccine

Jiangsu Recbio Technology Co., Ltd. has officially completed the enrollment process for the Phase III clinical trial of its new shingles vaccine, REC610. The vaccine, aimed at adults aged 40 and older, is being evaluated for both its efficacy and safety across multiple testing centers in China.

As the global market for shingles vaccines is currently dominated by GlaxoSmithKline’s Shingrix, there is growing demand for a domestic alternative. REC610 is positioned to fill this gap, offering a potential competitive edge in China’s vaccine market.

Related topics

• The Vital Link Between Skin Health and Long-Term Wellbeing
• How Ceramides and Peptides Are Shaping Skin Health in 2024
• KC Spotlight: Protecting Against Shingles This Holiday Season